Ovarian Cancer in BRCA Mutation Carriers: Improved Outcome After Intraperitoneal (IP) Cisplatin
Maryann Kwa(NYU Langone Health), Franco M. Muggia(NYU Langone Health), Susan Edwards(University of Southern California), Robert C. Wallach, Andrea Downey(University of New Mexico), Elsa Reich(Cancer Institute (WIA)), John P. Curtin(Cork University Hospital)
Cited by 30
Related Papers
The Intestinal Microbiome and Estrogen Receptor–Positive Female Breast Cancer
|JNCI Journal of the National Cancer Institute|2016|521
Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
|Journal of Clinical Oncology|2005|100
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.
|Journal of Clinical Oncology|1996|87